NKTXNkarta, Inc.
Pharmaceutical Preparations
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$113M
- 5.2% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | |
| Operating income | −$86M | −$119M | −$132M | −$128M | −$122M | 4.8% |
| Net income | −$86M | −$114M | −$118M | −$109M | −$104M | 4.3% |
| Operating cash flow | −$68M | −$57M | −$86M | −$100M | −$89M | 11% |
| Capex | $5M | $47M | $28M | $4M | $1M | 73% |
| Stock-based comp | $14M | $17M | $17M | $17M | $9M | 49% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $2M | 28 | — |
| FY2024 | $4M | $2M | 38 | — |